Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
Moniek P.M. de Maat, Adriano Henney(University of the Western Cape), Shu Ye(Shantou University), Aeilko H. Zwinderman(Amsterdam Neuroscience), Steve E. Humphries(University College London), J. Wouter Jukema(Leiden University Medical Center), John J.P. Kastelein(QRx Pharma (United States)), Payman Hanifi Moghaddam(Centre for Human Genetics), Ad J. van Boven(Leiden University), Cornelis Kluft(Leiden University Medical Center), Marian Beekman(Leiden University Medical Center), Albert V.G. Bruschke(Leiden University Medical Center)
Cited by 129
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k